Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

TOKYO–(BUSINESS WIRE)–$ARCT #ClinicalTrial–Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan. Meiji Seika … [Read more…]

Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive Officer

TOKYO–(BUSINESS WIRE)–Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from his current role of Representative Director, Executive Chairperson and CEO to Representative Director and Executive Chairperson while Mr. Okuzawa will transition to Representative … [Read more…]

Enveric Biosciences Announces Pricing of $5 Million Public Offering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents in … [Read more…]

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

— JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years — — JOURNAVX is an effective and well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain — BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals … [Read more…]

Athletes for Hope, Hilinski’s Hope, Kevin Love Fund and the Sarah Shulze Foundation Partner for Athlete Mental Health Week, February 1-9, 2025

Four nonprofit organizations seek to bring conversations about mental health to the forefront for athletes at every level NEW YORK–(BUSINESS WIRE)–Next week, four nonprofit organizations supporting mental health advocacy, Hilinski’s Hope Foundation (H3H), Athletes for Hope (AFH), the Kevin Love Fund (KLF) and the Sarah Shulze Foundation (SSF), will host the second annual Athlete Mental … [Read more…]

Heritable Agriculture Launches From X, The Moonshot Factory, to Improve Crops and Sustainably Feed the World

AI-driven biotechnology platform is designed to improve plants for higher yields, improved nutrition, and a more resilient global food and forestry system MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Heritable Agriculture, a project originally founded and incubated inside Alphabet’s moonshot factory, emerged from stealth today as an independent company focused on advancing plant breeding and biotechnology to make the … [Read more…]

CharmHealth Closes Out Another Stellar Year, Transforming Healthcare by Driving Innovation and Supporting Healthtech Companies and Entrepreneurs

Company Preps to Make an Even Bigger Impact in 2025 PLEASANTON, Calif.–(BUSINESS WIRE)–#AI—CharmHealth, a leader in healthcare technology solutions for providers, concluded 2024 solidifying its position as an innovation leader and facilitator. From partnerships and events to investments and product enhancements, CharmHealth consistently demonstrated its commitment to transforming healthcare delivery and enhancing provider and patient … [Read more…]

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis

Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in … [Read more…]

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

CEO Christophe Weber to retire from Takeda in June 2026 after 12 years Julie Kim, president of the U.S. Business Unit, named to succeed Weber after multi-year succession process OSAKA, Japan & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s … [Read more…]

Immunome Announces Pricing of Upsized Public Offering of Common Stock

BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 19,354,839 shares of its common stock at a price to the public of $7.75 per share. All of the shares are to be sold by Immunome. … [Read more…]